Sign in
4

Changes in Ownership

Xilio Therapeutics, Inc. Filed Acc 0001193125-26-002517

Chief Financial Officer sold 7,030 shares at $0.64 ($4,522)

  • Chief Financial Officer acquired 19,375 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Frankenfield Christopher James · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-01 Exercise or conversion : show line 1 in the form 10b5-1 +19,375 31,796 D
2026-01-02 Sale : show line 2 in the form 10b5-1 −7,030 $0.64 $4,522 24,766 D
Open-market sales · 7,030 sh · avg $0.64 · $4,522

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2025-12-31 Grant or award : show line 3 in the form 10b5-1 Stock Option (right to buy) +668,789 668,789 D
2026-01-01 Exercise or conversion : show line 4 in the form 10b5-1 Restricted Stock Units −19,375 38,750 D
Loading xslF345X05/ownership.xml…